Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

brain

- PMLiVE

Alzheimer’s Research UK calls for government action to address inequalities in dementia risk

The call comes as researchers presented findings demonstrating a link between socio-economic deprivation and higher dementia risk

- PMLiVE

Alzheimer’s Research UK welcomes ambitions for dementia set out in first women’s health strategy

The ten-year strategy follows the charity’s calls for action to tackle dementia’s disproportionate impact on women

- PMLiVE

Roche’s diagnostic test for Alzheimer’s receives FDA Breakthrough Device Designation

Alzheimer's affects more than 55 million people globally and is the most common form of dementia

Pharma, Technology, and Healthcare in the New Normal

Brian Canestraro, General Manager at Intercept Pharmaceuticals, discusses leadership lessons and tips to the impact of the COVID-19 pandemic on the way that Pharma conducts clinical trials and interacts with...

Impetus Digital

- PMLiVE

Alzheimer’s Research UK supports government plans for clinical research

The charity has suggested creating a Dementia Medicines Taskforce in order to address diseases like Alzheimer's

Scanning for Health Indicators and Risks Through Your Smartphone

Vlado Bosanac, Co-Founder & Head of Strategy and Revenue Growth at Advanced Human Imaging, dives into the implications of increased integration of tech and data into daily life for the...

Impetus Digital

- PMLiVE

Measure your omnichannel maturity with our new tool

Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness.

Avalere Health

- PMLiVE

The digital-first launch: the key to connected stakeholder experiences?

During the COVID-19 pandemic, a new digital-first launch model emerged as a gamechanger for driving better customer experiences. Here, Senior Consultant Srividya Sekar; Senior Associate Consultant, Erin Johnstone; and Associate...

Avalere Health

- PMLiVE

LifeArc partners with UK Dementia Research Institute

Dementia affects around 900,000 people in the UK and this is expected to rise to around 1.6 million by 2040

- PMLiVE

TauRx shares phase 3 trial data for Alzheimer’s drug

Those receiving the drug experienced a significantly slower decline than usual

- PMLiVE

BioXcel Therapeutics begins phase 3 trial for acute agitation in Alzheimer’s patients

There are no approved treatment options available for acute agitation related to dementia

Protecting Ownership of Technological & Pharmaceutical Innovation

Joshua Goldberg, Co-Managing Partner at Nath, Goldberg & Meyer, discusses key intellectual property issues and pitfalls in the digital health space, the importance of international patent protection, and why it’s...

Impetus Digital

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links